norclobazam (BioDeep_00000018038)

   

human metabolite Endogenous blood metabolite Chemicals and Drugs


代谢物信息卡片


8-chloro-4-hydroxy-1-phenyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one

化学式: C15H11ClN2O2 (286.0509016)
中文名称: 8-氯-1-苯基-1H-1,5-苯并二氮杂卓-2,4(3h,5h)-二酮
谱图信息: 最多检出来源 Homo sapiens(blood) 33.33%

分子结构信息

SMILES: C1C(=O)NC2=C(C=C(C=C2)Cl)N(C1=O)C3=CC=CC=C3
InChI: InChI=1S/C15H11ClN2O2/c16-10-6-7-12-13(8-10)18(11-4-2-1-3-5-11)15(20)9-14(19)17-12/h1-8H,9H2,(H,17,19)

描述信息

norclobazam is a metabolite of clobazam. Clobazam (marketed under the brand names Frisium, Urbanol and Onfi), is a drug which is a benzodiazepine derivative. It has been marketed as an anxiolytic since 1975 and an anticonvulsant since 1984. (Wikipedia)
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants

同义名列表

6 个代谢物同义名

8-chloro-4-hydroxy-1-phenyl-2,3-dihydro-1H-1,5-benzodiazepin-2-one; 8-chloro-4-hydroxy-1-phenyl-3H-1,5-benzodiazepin-2-one; N-Desmethyl Clobazam; N-Desmethylclobazam; Demethylclobazam; Norclobazam



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Astghik Mikayelyan, Armine Aleksanyan, Mariam Sargsyan, Arpine Gevorgyan, Hasmik Zakaryan, Armen Harutyunyan, Lusine Zhamharyan, Yeghig Armoudjian, Tigran Margaryan. Protein precipitation method for determination of clobazam and N-desmethylclobazam in human plasma by LC-MS/MS. Biomedical chromatography : BMC. 2020 Jan; 34(1):e4710. doi: 10.1002/bmc.4710. [PMID: 31630425]
  • Dwain Tolbert, Judy Gordon, Stuart Harris, Mark Walzer, Ihor Bekersky, Susan Reid. A Thorough QT/QTc Study of Clobazam in Healthy Volunteers. Clinical therapeutics. 2017 Oct; 39(10):2073-2086. doi: 10.1016/j.clinthera.2017.08.020. [PMID: 28958437]
  • Tyler E Gaston, E Martina Bebin, Gary R Cutter, Yuliang Liu, Jerzy P Szaflarski. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017 09; 58(9):1586-1592. doi: 10.1111/epi.13852. [PMID: 28782097]
  • Philip N Patsalos, Miguel Zugman, Charlotte Lake, Anthony James, Neville Ratnaraj, Josemir W Sander. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. Epilepsia. 2017 07; 58(7):1234-1243. doi: 10.1111/epi.13802. [PMID: 28542801]
  • Toshiyuki Iwasaki, Yutaka Nonoda, Tomoya Ishida, Taira Toki, Masahiro Ishii. Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy. Biomedical chromatography : BMC. 2017 Apr; 31(4):. doi: 10.1002/bmc.3848. [PMID: 27595429]
  • Margrete L Burns, Arton Baftiu, Mimi S Opdal, Svein I Johannessen, Cecilie Johannessen Landmark. Therapeutic Drug Monitoring of Clobazam and Its Metabolite-Impact of Age and Comedication on Pharmacokinetic Variability. Therapeutic drug monitoring. 2016 06; 38(3):350-7. doi: 10.1097/ftd.0000000000000272. [PMID: 26751267]
  • Vincent Jullien, Stéphanie Chhun, Elisabeth Rey, Olivier Dulac, Michel Tod, Catherine Chiron, Gérard Pons. Pharmacokinetics of clobazam and N-desmethylclobazam in children with dravet syndrome receiving concomitant stiripentol and valproic Acid. Clinical pharmacokinetics. 2015 May; 54(5):527-36. doi: 10.1007/s40262-014-0223-5. [PMID: 25503589]
  • Catherine Monteil-Ganiere, Jean-Michel Gaulier, Daniel Chopineaux, Lucia Barrios, Alain Pineau, Éric Dailly, Renaud Clément. Fatal anoxia due to rachacha consumption: Two cases reported. Forensic science international. 2014 Dec; 245(?):e1-5. doi: 10.1016/j.forsciint.2014.09.010. [PMID: 25450509]
  • Junji Saruwatari, Naoki Ogusu, Masatsugu Shimomasuda, Hiroo Nakashima, Takayuki Seo, Koji Tanikawa, Yoshiyuki Tsuda, Miki Nishimura, Rie Nagata, Norio Yasui-Furukori, Sunao Kaneko, Takateru Ishitsu, Kazuko Nakagawa. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. Therapeutic drug monitoring. 2014 Jun; 36(3):302-9. doi: 10.1097/ftd.0000000000000015. [PMID: 24345815]
  • Yoshiaki Yamamoto, Yukitoshi Takahashi, Katsumi Imai, Kou Miyakawa, Shigeko Nishimura, Risa Kasai, Hiroko Ikeda, Rumiko Takayama, Yukiko Mogami, Tokito Yamaguchi, Kiyohito Terada, Kazumi Matsuda, Yushi Inoue, Yoshiyuki Kagawa. Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy. Therapeutic drug monitoring. 2013 Jun; 35(3):305-12. doi: 10.1097/ftd.0b013e318283b49a. [PMID: 23666564]
  • Jose de Leon, Edoardo Spina, Francisco J Diaz. Clobazam therapeutic drug monitoring: a comprehensive review of the literature with proposals to improve future studies. Therapeutic drug monitoring. 2013 Feb; 35(1):30-47. doi: 10.1097/ftd.0b013e31827ada88. [PMID: 23318278]
  • Sarah E Aylett, Helen Cross, Dave Berry. Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. Developmental medicine and child neurology. 2006 Jul; 48(7):612-5. doi: 10.1017/s0012162206001289. [PMID: 16780634]
  • Mohammadreza Rouini, Yalda H Ardakani, Lida Hakemi, Maryam Mokhberi, Gheise Badri. Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 Sep; 823(2):167-71. doi: 10.1016/j.jchromb.2005.06.031. [PMID: 16005690]
  • Kenjiro Kosaki, Kazuyo Tamura, Reiko Sato, Hazuki Samejima, Yusuke Tanigawara, Takao Takahashi. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain & development. 2004 Dec; 26(8):530-4. doi: 10.1016/j.braindev.2004.02.010. [PMID: 15533655]
  • Antonia Parmeggiani, Annio Posar, Simonetta Sangiorgi, Paola Giovanardi-Rossi. Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. Brain & development. 2004 Jan; 26(1):63-6. doi: 10.1016/s0387-7604(03)00074-3. [PMID: 14729419]
  • Manuela Contin, Simonetta Sangiorgi, Roberto Riva, Antonia Parmeggiani, Fiorenzo Albani, Agostino Baruzzi. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Therapeutic drug monitoring. 2002 Dec; 24(6):737-41. doi: 10.1097/00007691-200212000-00009. [PMID: 12451290]
  • P K Kunicki. Simple and sensitive high-performance liquid chromatographic method for the determination of 1,5-benzodiazepine clobazam and its active metabolite N-desmethylclobazam in human serum and urine with application to 1,4-benzodiazepines analysis. Journal of chromatography. B, Biomedical sciences and applications. 2001 Jan; 750(1):41-9. doi: 10.1016/s0378-4347(00)00391-1. [PMID: 11204222]
  • K K Akerman. Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD. Scandinavian journal of clinical and laboratory investigation. 1996 Nov; 56(7):609-14. doi: 10.3109/00365519609090595. [PMID: 8981656]
  • R Herráez-Hernández, A J Louter, N C van de Merbel, U A Brinkman. Automated on-line dialysis for sample preparation for gas chromatography: determination of benzodiazepines in human plasma. Journal of pharmaceutical and biomedical analysis. 1996 Jun; 14(8-10):1077-87. doi: 10.1016/0731-7085(95)01703-8. [PMID: 8818018]
  • G W Roberts, G D Zoanetti. Clobazam and N-desmethylclobazam serum concentrations in endstage renal failure and hemodialysis. The Annals of pharmacotherapy. 1994 Jul; 28(7-8):966-7. doi: 10.1177/106002809402800730. [PMID: 7949528]
  • D F LeGatt, D P McIntosh. Clobazam and norclobazam quantitation in serum by capillary gas chromatography with electron-capture detection. Clinical biochemistry. 1993 Jun; 26(3):159-63. doi: 10.1016/0009-9120(93)90020-7. [PMID: 8101142]
  • J M Streete, D J Berry, J E Newbery. The analysis of clobazam and its metabolite desmethylclobazam by high-performance liquid chromatography. Therapeutic drug monitoring. 1991 Jul; 13(4):339-44. doi: 10.1097/00007691-199107000-00010. [PMID: 1780967]
  • A H Bardy, T Seppälä, T Salokorpi, M L Granström, P Santavuori. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain & development. 1991 May; 13(3):174-9. doi: 10.1016/s0387-7604(12)80025-8. [PMID: 1928610]
  • H Bun, S Monjanel-Mouterde, F Noel, A Durand, J P Cano. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacology & toxicology. 1990 Aug; 67(2):136-40. doi: 10.1111/j.1600-0773.1990.tb00799.x. [PMID: 2255665]
  • A Guberman, M Couture, K Blaschuk, A Sherwin. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. 1990 Aug; 17(3):311-6. doi: 10.1017/s031716710003064x. [PMID: 2207887]
  • W Löscher, C Rundfeldt. Development of tolerance to clobazam in fully kindled rats: effects of intermittent flumazenil administration. European journal of pharmacology. 1990 May; 180(2-3):255-71. doi: 10.1016/0014-2999(90)90309-t. [PMID: 2114299]
  • W R Gaździk, J Podleśny, M Filipek. HPLC method for simultaneous determination of clobazam and N-desmethylclobazam in human serum, rat serum and rat brain homogenates. Biomedical chromatography : BMC. 1989 Mar; 3(2):79-81. doi: 10.1002/bmc.1130030209. [PMID: 2736324]
  • N R Badcock, G D Zoanetti. Micro-determination of clobazam and N-desmethylclobazam in plasma or serum by electron-capture gas chromatography. Journal of chromatography. 1987 Oct; 421(1):147-54. doi: 10.1016/0378-4347(87)80390-0. [PMID: 2892847]
  • J R Haigh, T Pullar, J P Gent, C Dailley, M Feely. N-desmethylclobazam: a possible alternative to clobazam in the treatment of refractory epilepsy?. British journal of clinical pharmacology. 1987 Feb; 23(2):213-8. doi: 10.1111/j.1365-2125.1987.tb03032.x. [PMID: 3828198]
  • L J Dusci, L P Hackett. Simultaneous determination of clobazam, N-desmethyl clobazam and clonazepam in plasma by high performance liquid chromatography. Therapeutic drug monitoring. 1987; 9(1):113-6. doi: 10.1097/00007691-198703000-00019. [PMID: 3576656]
  • M I Arranz Peña, E Sanenz Lope. Determination of clobazam and its N-demethyl metabolite in serum of epileptic patients. Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie. 1986 Sep; 24(9):647-50. doi: 10.1515/cclm.1986.24.9.647. [PMID: 3772310]
  • H Bun, P Coassolo, F Gouezo, A Serradimigni, J P Cano. Time-dependence of clobazam and N-demethylclobazam kinetics in healthy volunteers. International journal of clinical pharmacology, therapy, and toxicology. 1986 Jun; 24(6):287-93. doi: NULL. [PMID: 3733278]
  • J L Tomasini, H Bun, P Coassolo, C Aubert, J P Cano. Determination of clobazam, N-desmethylclobazam and their hydroxy metabolites in plasma and urine by high-performance liquid chromatography. Journal of chromatography. 1985 Oct; 343(2):369-77. doi: 10.1016/s0378-4347(00)84605-8. [PMID: 4066878]
  • S Jawad, A Richens, J Oxley. Single dose pharmacokinetic study of clobazam in normal volunteers and epileptic patients. British journal of clinical pharmacology. 1984 Dec; 18(6):873-7. doi: 10.1111/j.1365-2125.1984.tb02558.x. [PMID: 6529527]
  • J R Haigh, J P Gent, R Calvert. Plasma concentrations of clobazam and its N-desmethyl metabolite; protection against pentetrazol-induced convulsions in mice. The Journal of pharmacy and pharmacology. 1984 Sep; 36(9):636-8. doi: 10.1111/j.2042-7158.1984.tb04917.x. [PMID: 6149294]
  • G Laux, D Koeppen. Serum and cerebrospinal fluid concentration of clobazam and N-desmethylclobazam. International journal of clinical pharmacology, therapy, and toxicology. 1984 Jul; 22(7):355-9. doi: NULL. [PMID: 6147313]
  • N Ratnaraj, V Goldberg, P T Lascelles. Determination of clobazam and desmethylclobazam in serum using high-performance liquid chromatography. The Analyst. 1984 Jul; 109(7):813-5. doi: 10.1039/an9840900813. [PMID: 6486453]
  • H R Ochs, D J Greenblatt, M Lüttkenhorst, B Verburg-Ochs. Single and multiple dose kinetics of clobazam, and clinical effects during multiple dosage. European journal of clinical pharmacology. 1984; 26(4):499-503. doi: 10.1007/bf00542148. [PMID: 6145596]
  • H G Grigoleit, P Hajdú, H K Hundt, D Koeppen, V Malerczyk, B H Meyer, F O Müller, P U Witte. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. European journal of clinical pharmacology. 1983; 25(1):139-42. doi: 10.1007/bf00544031. [PMID: 6617718]
  • A Brachet-Liermain, C Jarry, O Faure, M Guyot, P Loiseau. Liquid chromatography determination of clobazam and its major metabolite N-desmethylclobazam in human plasma. Therapeutic drug monitoring. 1982; 4(3):301-5. doi: 10.1097/00007691-198208000-00009. [PMID: 7135459]
  • M Divoll, D J Greenblatt, D A Ciraulo, S K Puri, I Ho, R I Shader. Clobazam kinetics: intrasubject variability and effect of food on adsorption. Journal of clinical pharmacology. 1982 Jan; 22(1):69-73. doi: 10.1002/j.1552-4604.1982.tb05711.x. [PMID: 7061729]